Zonegran zonisamide regulatory update

The Scottish Medicines Consortium (SMC) recommended the restricted use of Zonegran zonisamide from Eisai on the National Health Service (NHS) in Scotland as adjunctive therapy to treat partial seizures, with or without secondary generalization, in adolescents and children ages >=6 years - 1 of the drug's approved indications in the EU. SMC restricts the recommendation to use on advice from pediatric neurologists or pediatricians with an expertise in epilepsy. SMC already recommends the drug for the indication in adults, for which the drug is also approved in the EU. ...